therapeutic ratio

36
Therapeutic Ratios Dose Response Relationships and Therapeutic Ratio Normal Tissue Responses Alpha/Beta Overall Time Factor Tissue Organization Alternative Fractionation Schemes Predicting Responses Increasing Therapeutic Ratios

Upload: fondas-vakalis

Post on 07-May-2015

6.199 views

Category:

Health & Medicine


1 download

TRANSCRIPT

Page 1: Therapeutic Ratio

Therapeutic Ratios• Dose Response Relationships and

Therapeutic Ratio• Normal Tissue Responses

– Alpha/Beta– Overall Time Factor– Tissue Organization

• Alternative Fractionation Schemes– Predicting Responses

• Increasing Therapeutic Ratios

Page 2: Therapeutic Ratio

Dose-Response Relationships

Page 3: Therapeutic Ratio

Dose-Response Relationships

Page 4: Therapeutic Ratio

Very HighLymphocytes, immature hematopoietic cells, intestinal epithelium, spermatogonia, ovarian follicular cells

High

Urinary bladder epithelium, esophageal epithelium, gastric mucosa, mucous membranes, epidermal epithelium, epithelium of optic lens

Intermediate

Endothelium, growing bone and cartilage, fibroblasts, glial cells, glandular epithelium of breast, pulmonary epithelium, renal epithelium, hepatic epithelium, pancreatic epithelium, thyroid epithelium, adrenal epithelium

Low

Mature red cells, muscle cells, mature connective tissues, mature bone and cartilage, ganglion cells

TISSUE CLASIFICATIONS

Page 5: Therapeutic Ratio

TISSUE CLASIFICATIONSTISSUE TYPE

• Highly Differentiated Tissues– Little or no mitotic activity

– Closed static population

• Self-renewing tissue– Mitosis-Mediated Effects

– Rate of renewal (expression time)

TOXICITY MECHANISM

• Cell Killing Mediated– Inherent Radiosensitivity

– Response Related to Tissue Growth Kinetics

– Tissue Organization Important

• Not Obviously Mediated by Cell Killing– Nausea/Vomiting

– Fatigue, Somnolence

– Acute Edema

– Erythema

Page 6: Therapeutic Ratio

Early Effects• Early or acute effects occur within a few days of

irradiation

• Early or acute effects result from the death of large numbers of cells

• Response is determined by a hierarchical cell lineage composed of stem cells and their differentiated offspring

• Time to onset correlates with the relatively short lifespan of the mature functional cells

• The target cell is usually obvious

• Examples include skin epidermis, GI epithelium, and hematopoietic system

Page 7: Therapeutic Ratio

Late Effects• Late or chronic effects appear after a delay of

months

• Late effects occur predominately in slowly proliferating tissues

• Late damage is usually not completely reversible

• Targets for late damage include vascular and parenchymal cells

• Examples include lung, kidney, heart, liver and CNS

Page 8: Therapeutic Ratio

Dose-Response Curves

Page 9: Therapeutic Ratio

Dose-Response Curves

Withers, 1982

Page 10: Therapeutic Ratio

Early and Late Effects

Page 11: Therapeutic Ratio

Four R’s of Radiotherapy• Reoxygenation

• Reassortment of cells within the cell cycle

• Repair of Sublethal Damage

• Repopulation

Page 12: Therapeutic Ratio

Overall Time FactorExtra dose required to counteract proliferation does not become significant until ~2 weeks after the start of daily fractionation

Delay – population turnover time

Delay reflect mitotic death?

Steep Rise,

not T0.11

Denekamp, 1973 (Gray Lab)

Page 13: Therapeutic Ratio

Population Turnover Time• Therefore, effect of time in allowing sparing by cell

proliferation is large during RT for early responding tissues but absent or small for the late-responding organs

Treatment protocols are never sufficiently long to include proliferation of late-responding tissues

Page 14: Therapeutic Ratio

Accelerated Repopulation

28 Days

Withers: head and neck cancers

Dashed line: predicted from a constant 2 month clonogen doubling rate

Page 15: Therapeutic Ratio

Summary:Overall Time Effect

• Prolonged radiotherapy schedules:– Spare acute reactions and tumors but not late

complications

• Shortened radiotherapy schedules:– Will give more tumor cell kill, but the acute

reactions will also be more severe so that total dose must be reduced to some extent. Late reactions should not be worse

Page 16: Therapeutic Ratio

Functional Subunits in Tissues

• Can be structurally defined:– Survival of unit depends on the survival of one or

more clonogenic cells within unit– Small units more sensitive to radiation (smaller #s of

clonogens)– Examples: Kidney nephron, Liver lobule

• Can have no clear anatomic demarcation– Clonogenic cells can migrate from one unit to another– Tissue-rescue units– Examples: Bone marrow, Skin, Mucosa, Spinal cord

Page 17: Therapeutic Ratio

Volume Effect• The larger the irradiated volume of an organ

that is divided in FSUs, the greater the likelihood of knocking out enough subunits to effect the overall functioning of the tissue, and consequently, the lower the tolerance dose.

• Serial arrangement– Steep dose response– Example: spinal cord

• Loss of one FSU leads to myelopathy

• No serial arrangement– Less steep dose response– More usual condition

Page 18: Therapeutic Ratio
Page 19: Therapeutic Ratio

Volume Effect• Clinical tolerance depends strongly on

volume irradiated in:– Spinal cord, Kidney, Lung

• Skin– No well defined FSU but respond similar to

where FSUs are in parallel• Severity is dose independent• Larger area – potentially more problems

– Infection, prolonged healing time– Not based on increased probability of injury

Page 20: Therapeutic Ratio

Increasing Therapeutic Ratio

• Changing Dose/Fraction – Often leads to change in overall treatment

time– With fast-growing tumors, overall time may be

more important than fraction number– Between 5 and 7 weeks after the start of a

fractionated regimen, the dose equivalent of regeneration with protraction of treatment is ~0.5 Gy/day (3 Gy/week).

Page 21: Therapeutic Ratio

Alternative Fractionation Schemes

• Hyperfractionation

• Accelerated Treatment

• Continuous Hyperfractionation with Accelerated RT

• Accelerated Hyperfractionation RT while Breathing Carbogen and with the Addition of Nicotinamide

• Hypofractionation

Page 22: Therapeutic Ratio

Using Linear-Quadratic Concept to Calculate Effective Doses

• Emphasizes differences between early and late effects

• Never possible to match two different fractionation regimens to be equivalent for both

• Useful guide but not a substitute for clinical judgment and experience

Page 23: Therapeutic Ratio
Page 24: Therapeutic Ratio

Biologically Equivalent Doses (BED)

• BED is the quantity by which different fractionation regimens are compared.– Extrapolated tolerance dose

• Effect (e.g. cell kill) = n(d + d²)• E/ = nd(1+ d/())

– (1+ d/()) is the relative effectiveness term– E/(biologically equivalent dose)is the dose in Gy

required to produce some given endpoint such as tissue tolerance or complication rate of 5%

Page 25: Therapeutic Ratio

Predict the Effect of Hyperfractionation

• Conventional Treatment: 30 fractions of 2-Gy given one fraction per day, 5 days per week for an overall treatment time of 6 weeks.– 30F X 2Gy/6 weeks

• E/ = nd(1+ d/())

Page 26: Therapeutic Ratio

• Conventional Treatment: – 30F X 2Gy/6 weeks– E/ = nd(1+ d/())

• Early effects:– E/ = 60(1+ 2/(10)) = 72 Gy10

• Late effects:– E/ = 60(1+ 2/(3)) = 100 Gy3

Page 27: Therapeutic Ratio

Predict the effect of hyperfractionation

• Hyperfractionation: – 70F X 1.15 Gy twice daily/7 weeks– E/ = nd(1+ d/())

• Early effects:– E/ = 80.5(1+ 1.15/(10)) = 89.8 Gy10

• Late effects:– E/ = 80.5(1+ 1.15/(3)) = 114 Gy3

Page 28: Therapeutic Ratio

([35F X 1.8 Gy] + [12F X 1.5 Gy])/6 weeks

• Early effects:– E/ = 54(1+ 1.8/(10)) + 18(1+ 1.5/(10)) =

84.4 Gy10

• Late effects:

– E/ = 54(1+ 1.8/(3)) + 18(1+ 1.5/(3))113.4 Gy10

Concomitant Boost:

Page 29: Therapeutic Ratio

• N = N0et

N = number of clonogens at time t

– N0 = initial number of clonogens

– = constant related to Tpot• =loge²/Tpot = 0.693/Tpot

• E/ = nd(1+ d/()) – (0.693/)(t/Tpot)– (0.693/)(t/Tpot) = loge²/ (# of cell doublings)

Correction for Tumor Proliferation

Page 30: Therapeutic Ratio

• Assume = 0.3 ± 0.1/Gy

• Tpot = 2-25 days (5 day median)

• 30F X 2Gy/6 weeks (39 days)

• Early Effects:– (0.693/)(t/Tpot) = (0.693/0.3)(39/5) = 18 Gy10

• Late Effects:

Correction for Tumor Proliferation

Page 31: Therapeutic Ratio

Increasing Therapeutic Ratio

• Dose Distribution– IMRT– RIT

• DNA Damage– Halogenated

Pyrimidines

• Repair– High LET– Chemical Inhibitors

• Hypoxia– Hypoxic Cell

Sensitizers– Hyperbaric Oxygen– Transfusion

• Protection– Aminothiols– Cytokines

Page 32: Therapeutic Ratio

Halogenated Pyrimidines• BrdUrd (bromodeoxyuridine)• IdUrd (iododeoxyuridine)

– Take advantage of higher cell proliferation in tumors– Replace normal nucleotide precursor– Substituted DNA is more easily broken– Sensitization is seen at low dose rates, therefore it has

been used in conjunction with brachytherapy• Drugs are rapidly dehalogenated in liver, therefore it

is difficult to maintain high tumor levels for long times

• Also sensitizes to UV as well, therefore skin damage may be limiting (BrdUrd more so than IdUrd)

Page 33: Therapeutic Ratio

NitroimadazolesMetronidazole First compound studied

Minimal effects (at 10 mM, SER is 1.6)

Misonidazole Good SER (At 10 mM, eliminates effect of hypoxia on radiation sensitivity)

Preferential cytotoxicity to hypoxic cells that is increased with hyperthermia

Dose-limiting toxicity (peripheral neuropathy)

Poor results with fractionation

Etanidazole

Nimorazole

Short T½, less toxic

Doesn’t cross blood-brain barrier (less neurotoxic).

Not effective in RT trials

Less effective than others, but much less toxic

Promising results from H&N cancer RT trials

Page 34: Therapeutic Ratio

Hypoxic Cell Sensitzers• Overall – tumor control increase by 4.6%; survival by

2.8%; complication by 0.6%• Most trials in head and neck• Also potentiate cytotoxicity of:

– Melphalan, Bleomycin, Cisplatin– Cyclophosphamide, Nitrosourea

Hypoxic Cell Radiosensitization Tolerable doses of sensitizer are well below those

needed for maximum radiosensitization Fractionation reduces radiosensitization because of

reoxygenation Not all tumors in any one trial are hypoxic

Page 35: Therapeutic Ratio

Hypoxic Cell Cytoxins (Bioreductive Drugs)

• Selectively toxic to hypoxic cells• Metabolized to toxic products (usually radical ions) in

absence of oxygen• In the presence of oxygen, the toxic intermediate is

converted back to parent molecule

• Nitroimidazoles– Misonidazole– Etanidazole

• Quinones– Mitomycin C– Pofiromycin

• Benzotriazine di-N-Oxides– Tirapazamine

Page 36: Therapeutic Ratio

Phosphorothioates

• WR compounds• Metabolized into active thiols by phosphatase

enzymes• Effects parallel the oxygen effect

– Maximal for low LET– DRF range from 1-3

• Requires RT immediately following drug treatment

• Requires increasing overall dose• Not all tumors may respond similarly• Toxicity: not well tolerated